Patent · US Expired

Transiently immortalized cells

US6358739B1 · kind B1 · utility

22Cited by

2References

12Claims

0Family size

Assignee

Modex Therapeutiques, S.A. · CH

Inventors

Edward E. Baetge · Barrington, US
Shou Wong
Philippe Dupraz · Crissier, CH
Bernard Thorens · Épalinges, CH

Key dates

Filing date	Apr 10, 2000
Grant date	Mar 19, 2002
Priority date	—
Expiry date	Apr 10, 2020

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC12N2740/16322
WIPO fieldBiotechnology
WIPO sectorChemistry

Abstract

The invention provides methods and compositions for expanding cells that are not abundant or are difficult to obtain in pure form in culture, are in short supply (e.g., human cells), or have brief lifetimes in culture, using fusion polypeptide. The fusion polypeptide has a first region having the transport function of herpesviral VP22 protein or human immunodeficiency virus (HIV) TAT protein, and a second region with a polypeptide having cell immortalization activity, a polypeptide having telomerase-specific activity, or a polypeptide having telomerase gene activation activity. The resulting cells of the invention are suitable for use in cell therapy.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.